OTSU Stock Overview
Manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Otsuka Pakistan Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨159.95 |
| 52 Week High | PK₨185.89 |
| 52 Week Low | PK₨100.26 |
| Beta | 0.38 |
| 11 Month Change | 22.93% |
| 3 Month Change | 26.76% |
| 1 Year Change | 50.97% |
| 33 Year Change | -37.37% |
| 5 Year Change | -40.76% |
| Change since IPO | 855.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| OTSU | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 29.8% | 9.8% | 1.6% |
| 1Y | 51.0% | 140.5% | 46.1% |
Return vs Industry: OTSU underperformed the PK Pharmaceuticals industry which returned 140.4% over the past year.
Return vs Market: OTSU exceeded the PK Market which returned 47% over the past year.
Price Volatility
| OTSU volatility | |
|---|---|
| OTSU Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in PK Market | 9.6% |
| 10% least volatile stocks in PK Market | 3.6% |
Stable Share Price: OTSU's share price has been volatile over the past 3 months compared to the PK market.
Volatility Over Time: OTSU's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of PK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 345 | Moin-ur Rehman | www.otsuka.pk |
Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, which include pletaal and mucosta tablets, as well as oral rehydration therapy supplement for urinary tract. It engages in the trading of pharmaceutical products, nutritional foods, and medical equipment.
Otsuka Pakistan Limited Fundamentals Summary
| OTSU fundamental statistics | |
|---|---|
| Market cap | PK₨1.94b |
| Earnings (TTM) | -PK₨160.37m |
| Revenue (TTM) | PK₨3.18b |
0.6x
P/S Ratio-12.1x
P/E RatioIs OTSU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTSU income statement (TTM) | |
|---|---|
| Revenue | PK₨3.18b |
| Cost of Revenue | PK₨2.68b |
| Gross Profit | PK₨500.48m |
| Other Expenses | PK₨660.85m |
| Earnings | -PK₨160.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.25 |
| Gross Margin | 15.74% |
| Net Profit Margin | -5.04% |
| Debt/Equity Ratio | 192.9% |
How did OTSU perform over the long term?
See historical performance and comparison